Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
ANN ARBOR, Mich., Oct. 13, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that Brian Gibson has been named vice president of
ANN ARBOR, Mich., June 30, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that it will be included in the Russell Microcap ® Index, according
Aastrom Biosciences Announces $9.1 Million Private Placement of Common Stock Ann Arbor, Michigan, April 5, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that it has placed 8 million shares of common stock with institutional investors at approximately $1.14 per share, for an
Aastrom Biosciences Announces Appointment of Dr. Gunter Rosskamp as Managing Director of German Subsidiary Ann Arbor, Michigan, and Berlin, Germany, December 9, 2004 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) and Zellera AG (Zellera), its wholly-owned subsidiary, today announced that Gunter
ANN ARBOR, Mich., Oct. 29, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific, expanded multicellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that cell therapy regulatory and development expert
ANN ARBOR, Mich., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the closing of its previously announced underwritten public offering
